White paper
January 17, 2024

AAV Production in Culture Biosciences’ 250mL Bioreactors

Gene therapy manufacturing is often challenged by gaps in process understanding and lack of process robustness. Large-scale exploration of design space early in process development can help set foundation for robust manufacturing by identifying key process parameters. On-demand fleets of small-scale bioreactors by Culture Biosciences enable scientists to run large experiments with real-time data transparency. Download this App Note to learn about:

- Carrying out AAV upstream process development in Culture Biosciences' 250mL proprietary bioreactors

- Increase the fraction of full AAV capsids through process optimization

Complete the form to download the full PDF

Keep exploring

White paper

Comparison of AAV2 production in Culture Biosciences’ 250mL reactors vs commercially available 250mL bioreactors

January 2, 2025
White paper

AAV9 Process Robustness Evaluation in Cloud-native 250mL Bioreactors

November 19, 2024